-
2024-517232-22-00
5
2025-09-26
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
-
2024-519814-29-00
4
2025-09-12
Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-517167-23-00
5
2025-08-28
Chronic Hepatitis D Infection
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-519059-28-00
5
2025-07-17
Chronic Heart Failure
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2024-515566-13-00
5
2025-03-19
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-515020-36-00
9
2025-02-24
Advanced Solid tumour
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2024-511309-47-00
4
2024-07-17
moderate thrombocytopenia
-
2023-508162-15-00
5
2024-07-12
Chronic HF and comorbid impairment of kidney function who had a recent
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in